CORRESPONDENCE


(Accepted for publication February 9, 1998)

In Reply — It is interesting to know that Dr. Michael Rosen’s experience in terms of satisfaction with patient-controlled intravenous analgesia (PCIA) using meperidine during labor in a population of mixed social and economic status was similar to our experience. In our obstetric unit, although we allow nurses to initiate and maintain PCIA, an anesthesiologist is always available on an immediate basis.

Dr. Deborah Wilson’s concerns regarding the safety with PCIA and its effectiveness have been well discussed in our manuscript and in the accompanying editorial by Dr. David Chestnut published in the September 1997 issue of Anesthesiology. Our manuscript has clearly suggested that epidural analgesia provides better analgesia than PCIA during labor and that epidural analgesia should be preferred to PCIA. However, in view of the complete satisfaction expressed by 65–70% of women in the PCIA group and minimal crossover, it was reasonable to state that PCIA is also an effective method of pain relief during labor. Professor Rosen has supported this view in his letter to the editor. Regarding neonatal outcome, we have also clearly indicated in our manuscript that our primary purpose in the study was to evaluate the rate of cesarean section. However, in our manuscript there was no difference between the two groups with regards to immediate neonatal outcome in terms of objective criteria such as Apgar scores and cord pH, PCO₂, and PO₂, except for an increased requirement for naloxone in the PCIA group. Further, we had enough power to draw this conclusion (to determine a two-tailed significant difference of 0.05 between a mean ± SD umbilical arterial pH of 7.30 ± 0.06 and 7.25 ± 0.06 in the two groups for 80% power, only 24 acid base measurements per group are required). We did not compare neonatal neurobehavioral changes, so interpreting it either way would be incorrect. The clinical significance of subtle differences in neurobehavior is unclear. Overall our manuscript and the accompanying editorial clearly suggest that PCIA using meperidine is a reasonable option in some circumstances.

Shiv K. Sharma, M.D., F.R.C.A.
Assistant Professor
Department of Anesthesiology and Pain Management
University of Texas Southwestern Medical Center, Dallas
Dallas, Texas

Kenneth J. Leveno, M.D.
Professor
Department of Obstetric and Gynecology
University of Texas Southwestern Medical Center, Dallas
Dallas, Texas

(Accepted for publication February 9, 1998)

Preinsertion Pulmonary Artery Catheter Flushing

To the Editor — Since the introduction of central venous and pulmonary artery catheters into clinical practice, foreign body embolization from either guidewires1 or catheter shearing2 has been reported. We present this occurrence as the first reported case of potential foreign body embolization, unrelated to wires or catheter shearing, during pulmonary artery catheter insertion.

A 65-yr-old man was scheduled for sternal debridement, rewiring, and flap closure. The patient had sustained a recent myocardial infarction and a ventricular fibrillation arrest before surgery. He was now 10 days status after coronary artery bypass grafting (CABG), which was complicated by postoperative congestive heart failure (CHF). Current medications included lasix, digoxin, vasotec, potassium chloride, and aspirin.

Given the patient’s significant cardiac history and also the magnitude of the surgery, pulmonary artery catheter insertion was planned. After

Anesthesiology
1998; 88:1690–1
© 1998 American Society of Anesthesiologists, Inc.
Lippincott-Raven Publishers

Preinsertion Pulmonary Artery Catheter Flushing

To the Editor — Since the introduction of central venous and pulmonary artery catheters into clinical practice, foreign body embolization from either guidewires or catheter shearing has been reported. We present this occurrence as the first reported case of potential foreign body embolization, unrelated to wires or catheter shearing, during pulmonary artery catheter insertion.

A 65-yr-old man was scheduled for sternal debridement, rewiring, and flap closure. The patient had sustained a recent myocardial infarction and a ventricular fibrillation arrest before surgery. He was now 10 days status after coronary artery bypass grafting (CABG), which was complicated by postoperative congestive heart failure (CHF). Current medications included lasix, digoxin, vasotec, potassium chloride, and aspirin.

Given the patient’s significant cardiac history and also the magnitude of the surgery, pulmonary artery catheter insertion was planned. After
remnant from the manufacturing process. Another catheter was obtained, flushed, and inserted without incident. The rest of the anesthetic and surgery were uneventful.

We were fortunate that the lumen core was extruded during the flushing of the catheter ports before insertion into the patient. Had this not occurred until the catheter was inserted into the patient, it could have resulted in any one of several complications. Closer examination of the catheter revealed no additional problems. The manufacturer has no reports of a similar nature involving the same model and lot number. Moreover, the manufacturer has implemented several process improvements to prevent the type of occurrence reported herein. The Product Insert Data Sheet, included with each catheter, strongly recommends preinsertion testing of the catheter.

It is imperative that we pay close attention to the pulmonary artery catheter itself when flushing the ports because they may contain more that just heparinized saline solution.

The authors thank Drs. Roberta L. Hines and Paul G. Barash for their editorial review.

**Jane C. K. Fitch, M.D.**
Assistant Professor of Anesthesiology
Yale University School of Medicine
New Haven, Connecticut

**Xiao-En Fang, M.D.**
Associate Attending
Baylor University Medical Center
Dallas, Texas

**Michael L. Dewar, M.D.**
Assistant Clinical Professor of Cardiothoracic Surgery
Yale University School of Medicine
New Haven, Connecticut

**References**


(Accepted for publication February 22, 1998)

**JoAnne Smith Joyce**
Baxter International Inc.
Deerfield, Illinois

(Accepted for publication February 22, 1998)